Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Antiviral Drugs Could Come from DNA ‘Scrunching’

By University of Pennsylvania | June 9, 2016

This image shows gradual filling of viral capsid (blue oval, left panel) by DNA (yellow), which is driven into the capsid by the protein motor (red). Source: Stephen Harvey, PhD, Perelman School of Medicine, University of Pennsylvania

Evidence of DNA “scrunching” may one day lead to a new class of drugs against viruses, according to a research team from the Perelman School of Medicine at the University of Pennsylvania, the Georgia Institute of Technology, and Columbia University. The team is led by Stephen C. Harvey, PhD, an adjunct professor in the department of Biochemistry and Biophysics at Penn. The scientists report in The Journal of Physical Chemistry B that DNA may go through a repetitive cycle of contraction and elongation, or as they put it, “scrunching,” to generate the forces required to drive the DNA into a virus during replication. A better understanding of viral reproduction could be the basis of new ways to fight infectious pathogens.

During replication, viruses take over the host cell machinery to make copies of their genetic material and build protein shells called capsids to contain their genomic DNA or RNA. In some DNA viruses, such as herpesviruses, the empty capsid forms first, and the DNA is then packaged by a protein “motor” on the capsid.

In 2015, Harvey proposed that the traditional model in which the proteins push the DNA forward with a series of lever-like motions might be wrong. He suggested that the proteins might generate a cycle of DNA dehydration and rehydration. DNA is known to shorten by about 25 percent when it is dehydrated. He proposed that the resulting cycle of shortening and lengthening motions could be coupled to a DNA-protein grip-release cycle to generate forward motion. He called this the “scrunchworm model.”

“For some time now, we have been contemplating how viral DNA gets into the capsid so that one day we can block this step as a way to halt infection,” Harvey said. They tested the scrunchworm model in a series of computer simulations. The structures of the herpesviruses are not known with sufficient resolution to permit this kind of modeling, so the team examined DNA packaging in phi29, a DNA virus of similar structure that infects bacteria. They examined the interaction of DNA with the phi29 connector proteins, which form half of the protein motor. The DNA spontaneously underwent scrunching motions, without being pushed or pulled by protein levers. This provides the first support for the scrunchworm model.

It is essential to test the scrunchworm model experimentally, and Harvey has formed a collaboration with two other research groups to test predictions made by the scrunchworm model. These involve grabbing a single viral particle with a pair of “laser tweezers” and pulling on the DNA tail as the DNA is packaged. The model predicts that DNAs with different sequences will generate different amounts of force, and that DNA with RNA inserts cannot be packaged.

“Even if these experiments disprove the scrunchworm model, they will provide information that will help us figure out how these motors work,” Harvey said. “The purpose of modeling is to drive experiments and simulations that advance our understanding, regardless how they turn out.”


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE